



RAW SEQUENCE LISTING PATENT APPLICATION US/08/485,163

DATE: 10/29/97 TIME: 15:37:02

INPUT SET: S21268.raw

This Raw Listing contains the General Information Section and up to the first 5 pages.

	information Section and up to the first 3 pages.
L 2	SEQUENCE LISTING ENTERED
	General Information:
	(i) APPLICANT: Beaudry, Gary A. Maddon, Paul J.
	(ii) TITLE OF INVENTION: CD4-GAMMA2 CD4-IgG2 CHIMERAS
.*	iii) NUMBER OF SEQUENCES: 10
	(iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Cooper & Dunham LLP (B) STREET: 1185 Avenue of the Americas (C) CITY: New York (D) STATE: New York (E) COUNTRY: USA (F) ZIP: 10036
	(v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: PatentIn Release #1.24
	(VI) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: 08/485,163 (B) FILING DATE: 07-JUN-1995 (C) CLASSIFICATION:
	vii) ATTORNEY/AGENT INFORMATION: (A) NAME: White, John P. (B) REGISTRATION NUMBER: 28,678 (C) REFERENCE/DOCKET NUMBER: 37690-II-1-PCT-US
!	viii) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: (212) 278-0400 (B) TELEFAX: (212) 391-0525 (C) TELEX:
(2)	INFORMATION FOR SEQ ID NO:1:
	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 13 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: unknown

RAW SEQUENCE LISTING PATENT APPLICATION US/08/485,163



DATE: 10/29/97 TIME: 15:37:04

INPUT SET: S21268.raw

4/	(D) TOPOLOGY: unknown	
48		
49	(ii) MOLECULE TYPE: peptide	
50	(
51	(vi) ORIGINAL SOURCE:	
52	(A) ORGANISM: homo sapien	
53	(G) CELL TYPE: lymphocyte	
54		
55		
56		
57	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:	
58		
59	Phe Glu Arg Lys Cys Cys Val Gln Cys Pro Pro Cys Asp	
60	1 5 10	
61		
62	(2) INFORMATION FOR SEQ ID NO:2:	
63		
64	(i) SEQUENCE CHARACTERISTICS:	
65	(A) LENGTH: 1796 base pairs	
66	(B) TYPE: nucleic acid	
67	(C) STRANDEDNESS: double	
68	(D) TOPOLOGY: unknown	
69	(22) NOT BOUTE BURE DWA	
70	(ii) MOLECULE TYPE: cDNA	
71	(wi) ODIGINAL COURGE.	
72 73	<pre>(vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens</pre>	
73 74	(G) CELL TYPE: Lymphocyte	
75	(G) CELL TIPE: Lymphocyce	
76		
77		
78	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:	
79	(iii) bigoinoi bibonii iion big ib novi	
80	CAAGCCCAGA GCCCTGCCAT TTCTGTGGGC TCAGGTCCCT ACTGCTCAGC CCCTTCCTCC	60
81		
82	CTCGGCAAGG CCACAATGAA CCGGGGAGTC CCTTTTAGGC ACTTGCTTCT GGTGCTGCAA	120
83		
84 .	CTGGCGCTCC TCCCAGCAGC CACTCAGGGA AAGAAAGTGG TGCTGGGCAA AAAAGGGGAT	180
85	·	
86	ACAGTGGAAC TGACCTGTAC AGCTTCCCAG AAGAAGAGCA TACAATTCCA CTGGAAAAAC	240
87		
88	TCCAACCAGA TAAAGATTCT GGGAAATCAG GGCTCCTTCT TAACTAAAGG TCCATCCAAG	300
89		
90	CTGAATGATC GCGCTGACTC AAGAAGAAGC CTTTGGGACC AAGGAAACTT CCCCCTGATC	360
91		
92	ATCAAGAATC TTAAGATAGA AGACTCAGAT ACTTACATCT GTGAAGTGGA GGACCAGAAG	420
93	· · · · · · · · · · · · · · · · · · ·	•
94	GAGGAGGTGC AATTGCTAGT GTTCGGATTG ACTGCCAACT CTGACACCCA CCTGCTTCAG	480
95	🐞 ·	
96	GGGCAGAGCC TGACCCTGAC CTTGGAGAGC CCCCCTGGTA GTAGCCCCTC AGTGCAATGT	540
97		•
98	AGGAGTCCAA GGGGTAAAAA CATACAGGGG GGGAAGACCC TCTCCGTGTC TCAGCTGGAG	600

RAW SEQUENCE LISTING PATENT APPLICATION US/08/485,163

DATE: 10/29/97 TIME: 15:37:06

							• < 0						
100 101	CTCCAGGATA	GTGGCACCTG	GACATGCACT	GTCTTGCAGA		INPUT SET: S212 GGTGGAGTTC	660						
102 103	AAAATAGACA	TCGTGGTGCT	AGCTTTCGAG	CGCAAATGTT	GTGTCGAGTG	CCCACCGTGC	720						
104 105	CCAGGTAAGC	CAGCCCAGGC	CTCGCCCTCC	AGCTCAAGGC	GGGACAGGTG	CCCTAGAGTA	780						
106 107	GCCTGCATCC	AGGGACAGGC	CCCAGCTGGG	TGCTGACACG	TCCACCTCCA	TCTCTTCCTC	840						
108 109	AGCACCACCT	GTGGCAGGAC	CGTCAGTCTT	CCTCTTCCCC	CCAAAACCCA	AGGACACCCT	900						
110 111	CATGATCTCC	CGGACCCCTG	AGGTCACGTG	CGTGGTGGTG	GACGTGAGCC	ACGAAGACCC	960						
112 113	CGAGGTCCAG	TTCAACTGGT	ACGTGGACGG	CGTGGAGGTG	CATAATGCCA	AGACAAAGCC	1020						
114 115	ACGGGAGGAG	CAGTTCAACA	GCACGTTCCG	TGTGGTCAGC	GTCCTCACCG	TTGTGCACCA	1080						
116 117	GGACTGGCTG	AACGGCAAGG	AGTACAAGTG	CAAGGTCTCC	AACAAAGGCC	TCCCAGCCCC	1140						
118 119	CATCGAGAAA	ACCATCTCCA	AAACCAAAGG	TGGGACCCGC	GGGGTATGAG	GGCCACATGG	1200						
120 121	ACAGAGGCCG	GCTCGGCCCA	CCCTCTGCCC	TGGGAGTGAC	CGCTGTGCCA	ACCTCTGTCC	1260						
122 123	CTACAGGGCA	GCCCCGAGAA	CCACAGGTGT	ACACCCTGCC	CCCATCCCGG	GAGGAGATGA	1320						
124 125	CCAAGAACCA	GGTCAGCCTG	ACCTGCCTGG	TCAAAGGCTT	CTACCCCAGC	GACATCGCCG	1380						
126 127	TGGAGTGGGA	GAGCAATGGG	CAGCCGGAGA	ACAACTACAA	GACCACACCT	CCCATGCTGG	1440						
128 129	ACTCCGACGG	CTCCTTCTTC	CTCTACAGCA	AGCTCACCGT	GGACAAGAGC	AGGTGGCAGC	1500						
130 131	AGGGGAACTG	CTTCTCATGC	TCCGTGATGC	ATGAGGCTCT	GCACAACCAC	TACACGCAGA	1560						
132 133	AGAGCCTCTC	CCTGTCTCCG	GGTAAATGAG	TGCCACGGCC	GGCAAGCCCC	CGCTCCCCAG	1620						
134 135	GCTCTCGGGG	TCGCGTGAGG	ATGCTTGGCA	CGTACCCCGT	GTACATACTT	CCCAGGCACC	1680						
136 137	CAGCATGGAA	ATAAAGCACC	CAGCGCTGCC	CTGGGCCCCT	GCGAGACTGT	GATGGTTCTT	-1740						
138 139	TCCGTGGGTC	AGGCCGAGTC	TGAGGCCTGA	GTGGCATGAG	GGAGGCAGAG	TGGGTC	1796						
140 141	(2) INFORM	ATION FOR SE	EQ ID NO:3:										
142 143 144 145 146 147	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 432 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) FOPOLOGY: unknown												
148 149	į	OLECULE TYPE	_										
150 151 152	· · · · · · · · · · · · · · · · · · ·		RCE: 4: homo sapi PE: lymphocy										



153

RAW SEQUENCE LISTING PATENT APPLICATION US/08/485,163

8

DATE: 10/29/97 TIME: 15:37:09

INPUT SET: S21268.raw

153																
154																
155																
156	(xi)	SEQ	JENCI	E DE	SCRI	PTIO	N: SI	EQ I	ON C	:3:						
157																
158	Met	Asn	Arg	Gly	Val	Pro	Phe	Arg	His	Leu	Leu	Leu	Val	Leu	Gln	Leu
159	1				5					10					15	
160																
161																
162	Ala	Leu	Leu	Pro	Ala	Ala	Thr	Gln	Gly	Lys	Lys	Val	Val	Leu	Gly	Lys
163				20					25	-	_			30	-	-
164																
165																
166	Lvs	Gly	Asp	Thr	Val	Glu	Leu	Thr	Cvs	Thr	Ala	Ser	Gln	Lvs	Lvs	Ser
167	-1-	1	35					40	- 1				45	-1-	-1-	
168								- •								
169																
170	Tle	Gln	Phe	His	Trn	T.VS	Δsn	Ser	Δsn	Gln	Tle	T.vs	Tle	T.e.11	Glv	Δsn
171		50				_,_	55	201		· · · · ·		60			011	
172		50					-					•				
173																
174	Gln	Gly	Ser	Phe	T.eu	Thr	T.VS	Glv	Pro	Ser	T.vs	Len	Asn	Asn	Δra	Δla
175	65	01,	201	1		70	-,-	01,			75	400		nop	****9	80
176						, 0					, 5					00
177																
178	Acn	Ser	Ara	120	Sor	LOU	Trn	Nen	Gln	Gl v	λen	Dha	Dro	LON	Tla	Tla
179	АЗР	DCI	AL 9	ALG	85	пец	пр	изр	0111	90	ASII	1110	110	пса	95	116
180			-		O,S					70					75	
181																
182																
183	T.vs	Asn	T. 211	T.vs	Tle	Glu	Agn	Ser	Asn	Thr	Tur	Tle	Cvs	Glu	Val	Glu
184	_,_			100		<u></u>	p	501	105		- 7 -		0,5	110	,	<u></u>
185				-00					105							
186																
187	Nen	Gln	Tue	@lu	Glu	Val	aln	T 011	T 011	Val	Dha	G1 v	T 611	Thr	λla	λen
188	тор	GIII	115	GIG	GIG	Val		120	пеа	*41	1110	GLY	125	1111	AIG	ASII
189								120					123			
190							•									
191	Sar	Asp	Thr	Hie	T.011	T.411	Gln	G] v	al n	Sar	T.OH	Ühr	T.011	Пhr	T. 611	Glu
192	Ser	130	1111	птэ	Leu	Leu	135	СТУ	GIII	Set	neu	140	ьеи	1111	Dea	GIU
193		130					133					140				
194																
194	~~~	D===	Dma	a1	C	C	Dwa	C	v. 1	~1 ~	a		C	Dwa	N	a1
195		Pro	PIO	GIY	ser	150	PIO	Set	vат	GIN	_	Arg	Set	PLO	Arg	_
	145					120					155	:				160
197	T	3 ~ ~	T1.	a1	a1	a1	T	mb	T a	C	v. 1.		71 5	T	a1	T
198	ьys	Asn	тте	GIN	_	стλ	гÀг	Thr	ьeu		vaT;	ser		ьeu		ьeu
199					165					170	3		6		175	
200											į					
201	~ 7	_	_	~ 7	1	_	1	_	-1		_ <i>4</i>	, , ,		7	_	_
202	GIN	Asp	ser	_	Thr	Trp	Thr	cys		val	ren.	GIN	Asn		гàг	гàг
203				180					185		ŧ		•	190		
204											\$		÷ ,			
205											į		•			

Mary Art

258

RAW SEQUENCE LISTING PATENT APPLICATION US/08/485,163

DATE: 10/29/97 TIME: 15:37:12

								0-			,.					******
		,*											IN	PUT S	ET: S	321268.raw
206	Val	Glu	Phe	Lys	Ile	Asp	Ile	Val	Val	Leu	Ala	Phe				
207			195	-1-		E		200					205	3	-1-	-3
208	-															
209																
210	Cvs	Val	Glu	Cys	Pro	Pro	Cvs	Pro	Δla	Pro	Pro	Va1	Ala	Glv	Pro	Ser
211	0,0	210		0,5			215					220		1		501
212							220									
213											,					
214	Val	Phe	T.011	Phe	Pro	Pro	T.ve	Pro	T.vs	Asn	Thr	T.e.11	Met	Tle	Ser	Ara
215	225		200		110	230	2,0		_,_	11.55	235	200				240
216	225					250										210
217	Thr	Pro	Glu	Val	Thr	Cvs	Val	Val	Va1	Asp	Val	Ser	His	Glu	Asn	Pro
218		110	OIU	*41	245	O y S	*41	*41	*4.	250	,,,	501	*****	014	255	
219					210					200					200	
220 .																
221	Glu	Val	Gln	Phe	Asn	Trn	Tvr	Val	Asp	Glv	Val	Glu	Val	His	Asn	Ala
222			•	260		P			265					270		
223				200					200					2,0		
224																
225	T.vs	Thr	I.vs	Pro	Ara	Glu	Glu	Gln	Phe	Asn	Ser	Thr	Phe	Ara	Va1	Val
226	-,-		275		9			280					285	5		
227			2,5					200					200			
228																
229	Ser	Val	Leu	Thr	Val	Val	His	Gln	Asp	Trp	Leu	Asn	Glv	ī.vs	Glu	Tur
230	201	290			,	,	295					300	,	-,-		- , -
231																
232																
233	Lvs	Cvs	Lvs	Val	Ser	Asn	Lvs	Glv	Leu	Pro	Ala	Pro	Ile	Glu	Lvs	Thr
234	305	-,-	-,-			310	-,-	1			315				-1-	320
235																
236	Ile	Ser	Lvs	Thr	Lvs	Glv	Gln	Pro	Ara	Glu	Pro	Gln	Val	Tvr	Thr	Leu
237			-4-		325	1			5	330				- 4 -	335	
238																
239							•									
240	Pro	Pro	Ser	Arg	Glu	Glu	Met	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cvs
241				340					345					350		•
242																
243																
244	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser
245			355	_		_		360	_				365	_		
246																
247		•														
248	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Met	Leu	Asp
249		370					375					380				
250													,			
251													-			
252	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser
253	385		_			390		•			395		Ì			400
254													٩			
255													;			
256	Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met	Hiş	Glu	Ala
257	_	-			405					410			į	:	415	
259													7			



DATE: 10/29/97 TIME: 15:37:14

INPUT SET: S21268.raw

Line

Error

Original Text